GenVec, Inc. reported today that the U.S. Food and Drug Administration (FDA) has approved GenVec’s TNFerade™ for Fast Track development in the treatment of locally advanced pancreatic cancer. TNFerade™ is designed to stimulate the production of immune system proteins with anti-cancer properties that are injected into tumors.

China Pharma Holdings Inc. (OTCBB: CPHI) develops, manufactures and markets generic and branded specialty pharmaceutical products in China. The company today announced its third-quarter results for the period ended September 30, 2008, marking significant increases in revenues and net income.

BioScrip, Inc., the specialty pharmacy and pharmacy services provider, had a double dose of good news today with the announcement of exceptional second quarter revenue and earnings figures. Consolidated revenue grew to $348.4 million, an 18.2% increase over the same period last year. Specialty Services revenue shot up to $298.2 million, a 25.3% over the prior year.

Oxygen Biotherapeutics Inc. (OTCBB: OXBO) engages in marketing innovative pharmaceuticals and medical devices to monitor respiration in patients suffering from or associated with respiratory distress syndrome, stroke, myocardial infarction, surgery, trauma, malignant tumors and diabetes.

Investing in the pharmaceutical world means trying to invest as a product gets closer to completing FDA trials and approvals. In many respects, this is a wise strategy as a negative review by the FDA can kill a drug and its sponsor right along with it.

Dyax Corp. (Nasdaq: DYAX) focuses on the advancement of novel biotherapeutics, such as those for the treatment of hereditary angiodema (HAE), a rare and potentially life-threatening condition that occurs in about one in every 10,000 to 50,000 people.

Dutton Associates, one of the largest independent investment research firms in the United States, today announced it is reiterating its “Strong Speculative Buy” rating with a higher price target of $1.50 for Neoprobe Corp. (OTCBB: NEOP), a biomedical company forecast to generate profit in the second half of 2010 with earnings per share of 12 cents for the full year.

For shareholders of Pfizer, Inc. (PFE) stock, it has been a pretty barren decade. No investor can look at Pfizer’s ten year chart and miss the fact that the stock has been a multi-year dog. However, from a valuation standpoint, these high-yielding shares are worthy of consideration for patient, income-oriented investors.

Dyax Corp. (Nasdaq: DYAX) is a clinical-stage drug company focused on the discovery, development and commercialization of biotherapeutics for oncology and inflammatory conditions.

China Medicine Corporation (CHME.OB), a developer and distributor of pharmaceuticals and nutritional supplements in China, reported strong second quarter financial results this morning. Revenues increased 40.8% year over year to $11.6 million, compared to $8.3 million in Q2 2007. Net income soared 118.8% to $2.5 million, or 16 cents per share, vs. $1.1 million, or 8 cents per share a year ago.

Stock Analysis of Abbott Laboratories (ABT). The analysis includes a detailed PDF.

SGX Pharmaceuticals is a biopharmaceutical company which focuses mainly on the development and commercialization of new oncological, or cancer therapies. Yesterday, the company announced its submission of an Investigational New Drug (IND) application for FDA approval.

Stock Analysis of Eli Lilly and Co. (LLY). The analysis includes a detailed PDF.

Unigene Labs Inc., a biopharmaceutical company, works to develop and market peptide and other related pharmaceuticals. The company currently has an estimated 55% market share of the prescription nasal congestion marketplace and is entering Phase III trials with a new calcintonin product.

The company announced a letter of agreement with the Sanquin Blood Supply Foundation, which gives Lev the OK to file for European marketing authorization of C1 to treat the life-threatening attacks associated with HAE, such as inflammation of the larynx, abdomen, face, extremities and urogenital tract.